https://orcid.org/0000-0003-1056-6609
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
"COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies." Human Vaccines & Immunotherapeutics, 18(1), pp.
Disclosure of potential conflicts of interest
NE and AC declare having no financial conflicts of interest. NE serves on the board of advisors for 1DaySooner, an organization of intended volunteers for SARS-CoV-2 challenge trials–an unpaid position. AC provides unpaid advice to Moderna and J&J on their vaccines. SP works with several companies in the development of SARS-CoV-2 vaccinations.
Competing interests
No competing interests were disclosed.
Additional information
Funding
NE receives funding from the U.S. Department of Health and Human Services- National Institutes of Health (National Institute of Allergy and Infectious Disease) [Award #AI114617- 01A1]; National Science Foundation [Award # 2039320]; Open Philanthropy.